Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2003 1
2007 1
2008 1
2012 1
2014 2
2015 3
2016 2
2018 3
2019 4
2020 5
2021 5
2022 7
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 22dutch
Page 1
Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation.
Manderlier M, Navez J, Hein M, Engelholm JL, Closset J, Bali MA, Van Gestel D, Moretti L, Van Laethem JL, Bouchart C. Manderlier M, et al. Cancers (Basel). 2022 Nov 22;14(23):5730. doi: 10.3390/cancers14235730. Cancers (Basel). 2022. PMID: 36497212 Free PMC article.
Given the lack of direct comparative evidence, we aimed to compare the oncological outcomes of localized pancreatic ductal adenocarcinoma (PDAC) treated in the same tertiary cancer center with isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT) or conventio …
Given the lack of direct comparative evidence, we aimed to compare the oncological outcomes of localized pancreatic ductal adenocarci …
Influence of intraoperative blood salvage and autotransfusion on tumor recurrence after deceased donor liver transplantation: a large nationwide cohort study.
Yang M, Wei X, Shu W, Zhai X, Zhou Z, Cai J, Yang J, Jin B, Zheng S, Xu X. Yang M, et al. Int J Surg. 2024 Sep 1;110(9):5652-5661. doi: 10.1097/JS9.0000000000001683. Int J Surg. 2024. PMID: 38847771 Free PMC article.
Postmatching, the cumulative recurrence rate and recurrence-free survival rate revealed no significant difference in the IBSA group and non-IBSA group (22.4 vs. 16.5%, P =0.12; 60.3 vs. 60.9%, P =0.74). Recipients beyond Milan criteria had higher, albeit not signifi …
Postmatching, the cumulative recurrence rate and recurrence-free survival rate revealed no significant difference in the IBSA group and non- …
Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma.
Shin DW, Park J, Lee JC, Kim J, Kim YH, Hwang JH. Shin DW, et al. Cancers (Basel). 2022 May 18;14(10):2476. doi: 10.3390/cancers14102476. Cancers (Basel). 2022. PMID: 35626080 Free PMC article.
Results: Two hundred ninety-eight patients with PDA (159 with resectable pancreatic cancer (RPC) and 139 with borderline resectable pancreatic cancer (BRPC)/locally advanced pancreatic cancer (LAPC)) were included. ...Well-enhanced PDA du …
Results: Two hundred ninety-eight patients with PDA (159 with resectable pancreatic cancer (RPC) and 139 with borderline resec …
Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma.
Altshuler E, Aryan M, Kallumkal G, Gao H, Wilson J, Ouni A, De Leo E, Hanayneh W, Pan K. Altshuler E, et al. Hepat Oncol. 2022 May 24;9(2):HEP43. doi: 10.2217/hep-2021-0010. eCollection 2022 Apr. Hepat Oncol. 2022. PMID: 35665305 Free PMC article.
BACKGROUND: beta-blockers (BBs) have shown promise in improving overall survival (OS) in patients with breast, ovarian, pancreatic and lung cancer. However, few studies have evaluated the impact of BBs on unresectable hepatocellular carcinoma (HCC). ...RESULTS: Ther …
BACKGROUND: beta-blockers (BBs) have shown promise in improving overall survival (OS) in patients with breast, ovarian, pancreatic an …
Postoperative pancreatic fistula after robot distal gastrectomy.
Seo HS, Shim JH, Jeon HM, Park CH, Song KY. Seo HS, et al. J Surg Res. 2015 Apr;194(2):361-366. doi: 10.1016/j.jss.2014.10.022. Epub 2014 Oct 22. J Surg Res. 2015. PMID: 25454974 Clinical Trial.
MATERIALS AND METHODS: A total of 40 patients with gastric cancer who underwent RADG were compared with 40 initial patients who underwent LADG by a single surgeon. ...RESULTS: The POPF was observed more frequently in the LADG group than in the RADG group (22. …
MATERIALS AND METHODS: A total of 40 patients with gastric cancer who underwent RADG were compared with 40 initial patients who under …
Reduced pancreatic fistula rates and comprehensive cost analysis of robotic versus open pancreaticoduodenectomy.
Wakabayashi T, Gaudenzi F, Nie Y, Mishima K, Fujiyama Y, Igarashi K, Teshigahara Y, Mineta S, Bozkurt E, Wakabayashi G. Wakabayashi T, et al. Surg Endosc. 2025 Jun;39(6):3921-3929. doi: 10.1007/s00464-025-11768-4. Epub 2025 May 12. Surg Endosc. 2025. PMID: 40355734 Free PMC article.
BACKGROUND: Robotic pancreaticoduodenectomy (RPD) has emerged as a promising surgical approach for the treatment of periampullary neoplasms, offering the potential benefits of minimally invasive surgery. However, the impact of RPD on clinically relevant pancreatic f …
BACKGROUND: Robotic pancreaticoduodenectomy (RPD) has emerged as a promising surgical approach for the treatment of periampullary neoplas …
Perioperative and long-term outcome of en-bloc arterial resection in pancreatic surgery.
Wiltberger G, den Dulk M, Bednarsch J, Czigany Z, Lang SA, Andert A, Lamberzt A, Heij LR, de Vos-Geelen J, Stommel MWJ, van Dam RM, Dejong C, Ulmer F, Neumann UP. Wiltberger G, et al. HPB (Oxford). 2022 Jul;24(7):1119-1128. doi: 10.1016/j.hpb.2021.12.003. Epub 2021 Dec 14. HPB (Oxford). 2022. PMID: 35078714 Free article.
BACKGROUND: Pancreatic tumors are frequently diagnosed in a locally advanced stage with poor prognosis if untreated. ...Median disease-free survival and median overall survival were for the R0/CRM- group 22.8 months and 27.9 months, 9.5 and 19.8 months for th …
BACKGROUND: Pancreatic tumors are frequently diagnosed in a locally advanced stage with poor prognosis if untreated. ...Median diseas …
Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival?
Macedo FI, Picado O, Hosein PJ, Dudeja V, Franceschi D, Mesquita-Neto JW, Yakoub D, Merchant NB. Macedo FI, et al. Pancreas. 2019 Jul;48(6):823-831. doi: 10.1097/MPA.0000000000001339. Pancreas. 2019. PMID: 31210664
OBJECTIVES: The objective of this study was to evaluate the role of lymph node (LN) dissection and staging in outcomes of patients with pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy (NAC). METHODS: National Cancer Database was queried for p …
OBJECTIVES: The objective of this study was to evaluate the role of lymph node (LN) dissection and staging in outcomes of patients with p …
A score model based on pancreatic steatosis and fibrosis and pancreatic duct diameter to predict postoperative pancreatic fistula after Pancreatoduodenectomy.
Xingjun G, Feng Z, Meiwen Y, Jianxin J, Zheng H, Jun G, Tao H, Rui Z, Leida Z, Min W, Renyi Q; FACS. Xingjun G, et al. BMC Surg. 2019 Jul 3;19(1):75. doi: 10.1186/s12893-019-0534-4. BMC Surg. 2019. PMID: 31269932 Free PMC article.
Pancreatic Fibrosis (PF) and Pancreatic Steatosis (PS) were assessed by pathological examination of the pancreatic stump. ...And patients were stratified into high-risk group (22~28 points), medium-risk group (15~21 points) and low-risk group (8 …
Pancreatic Fibrosis (PF) and Pancreatic Steatosis (PS) were assessed by pathological examination of the pancreatic stum …
p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis.
Rosty C, Geradts J, Sato N, Wilentz RE, Roberts H, Sohn T, Cameron JL, Yeo CJ, Hruban RH, Goggins M. Rosty C, et al. Am J Surg Pathol. 2003 Dec;27(12):1495-501. doi: 10.1097/00000478-200312000-00001. Am J Surg Pathol. 2003. PMID: 14657708
Of 405 duct lesions identified in the chronic pancreatitis group, 7.6% were reactive changes, 65.5% were PanIN-1A, 18% were PanIN-1B, 7.4% were PanIN-2, and 1.5% were PanIN-3. Within the pancreatic endocrine tumor group, 22 PanINs were identified: 15 PanIN-1A …
Of 405 duct lesions identified in the chronic pancreatitis group, 7.6% were reactive changes, 65.5% were PanIN-1A, 18% were PanIN-1B, 7.4% w …
37 results